MODERN GLOBAL DRUG DEVELOPMENT

KoBIA-Covance Seminar

Monday, 25 September 2017 | 13:00 – 17:00

Sheraton Seoul Palace Gangnam Hotel
160 Sapyeong-daero, Seocho-gu, Seoul, South Korea
1FL, Royal Ballroom

Modern drug development is quickly evolving and sponsors are facing increasing pressure to decrease timelines and increase efficiencies. Join our symposium with several scientific and operational thought leaders to:

- Understand the effect of a rapidly changing drug development environment
- Hear insights on how to overcome operational and scientific challenges
- Learn about strategic solutions for both the Asia Pacific region and the global community

SPEAKERS

Trends in Pharmaceutical Drug Development

Eric Lang, MD
Vice President, Global Head, Clinical Drug Development Strategists, Covance

Dr. Lang currently heads a group within Covance that supports our clients in identifying solutions to transition their clinical programs efficiently through the various phases of clinical development. Dr. Lang has more than 19 years of experience in pharmaceutical development in both large and small pharma. His experience includes leading drug development teams that have successfully filed NDAs, directing clinical operations, clinical development, pharmaceutical business development, and designing, planning, and directing regulatory strategies. Dr. Lang has negotiated with the FDA regarding clinical and regulatory development programs for drug and device approvals. Prior to working at Covance, Dr. Lang was vice president, head of clinical development for Grünenthal USA Inc. Before that he was vice president of clinical research at Javelin Pharmaceuticals and also held positions of head of clinical research and development at Novartis Consumer Health as well as pain and executive director of licensing and new business development at Johnson and Johnson. Dr. Lang received his MD from Ben Gurion University of the Negev in Beer Sheba, Israel. He completed a fellowship in clinical research and in pain management at Emory University Medical School in Atlanta, Georgia. He is a board certified anesthesiologist and pain management specialist and has been published in many peer-reviewing research papers as well as book chapters and review articles.

KoBIA
Korea Biomedicine Industry Association
한국바이오의약품협회

COVANCE
SOLUTIONS MADE REAL®

SPEAKERS *(continued)*

Development of Immuno-Oncology Drugs: Current Status and Future Perspectives

Yung-Jue Bang, MD, PhD
Professor of Medical Oncology, Seoul National University Hospital

Dr. Bang has more than 30 years of experience and has researched several oncology treatments in Phase III trials for gastric cancer as well as non-small cell lung cancer and pancreatic neuroendocrine tumors. He currently works at the Seoul National University Hospital as a professor of medical oncology, president of the Biomedical Research Institute and director of the Clinical Trials Center. Dr. Bang was the principal investigator on a number of international clinical trials, such as ToGA, CLASSIC, SHINE, and GOLD studies. He received his MD and PhD from Seoul National University in Korea and completed his post-doctoral studies at the National Cancer Institute in the US.

Immuno-Oncology Clinical Development and Adaptive Design

Naftali Bechar, MD
Senior Director, Clinical Drug Development Strategist, Covance

Dr. Bechar is a senior clinical drug development strategist at Covance, providing clinical and drug development input. He provides consulting for early clinical drug development CDP, TTP and protocol design projects in oncology. Dr. Bechar has expertise in immuno-oncology drug development and using adaptive design/basket study designs in this field.

Insights and Approaches to Companion Diagnostics Development

Thomas Turi, PhD
Vice President Companion Diagnostics, Covance Laboratories

Dr. Turi joined Covance in 2008 to establish the biomarker center of excellence and currently develops and coordinates science and strategy for biomarkers, companion diagnostics and technology across Covance. He has more than 20 years of experience in drug discovery and development and leads operations for the newly launched companion diagnostics development laboratory.

Programmatic Outsourcing: A Timely Approach to Drug Development

Bill Hanlon, PhD
Chief Development Officer and Head of Global Regulatory Affairs, Covance

Dr. Hanlon has been an active contributor to the development of innovative new medicines for almost 30 years. Dr. Hanlon currently leads a group of more than 180 regulatory, medical writing and strategic drug development professionals. Dr. Hanlon's team provides pharmaceutical and biotech companies with a broad array of regulatory and drug development consulting solutions to help bring innovative products to market around the world.

KoBIA
Korea Biomedicine Industry Association
한국바이오의약품협회

COVANCE®
SOLUTIONS MADE REAL®

SPEAKERS *(continued)*

Assessing Abuse Potential of CNS-Active Compounds

Beatriz Rocha, MD, PhD
Executive Director, Head of Regulatory Affairs & Clinical Strategy, Covance

Dr. Rocha has more than 30 years of professional experience spanning from academia to government to industry. As a board-certified anesthesiologist and behavioral pharmacologist, Dr. Rocha spent 20 years in clinical and laboratory practice before joining Merck in 2001. She is an expert in addiction and abuse liability. At Covance, Dr. Rocha currently provides strategic regulatory input for internal and external customers, including working with clients and global regulatory agencies in the organization and preparation of clinical development plans and agency interactions.

We look forward to your attendance. Please RSVP to:

https://attendesource.com/profile/form/index.cfm?PKformID=0x1012902083

Learn more about our drug development solutions at **www.covance.com**

The Americas + 1.888.COVANCE (+1.888.268.2623) + 1.609.452.4440
Europe / Africa + 00.800.2682.2682 +44.1423.500888
Asia Pacific + 800.6568.3000 +65.6.5686588

KoBIA
Korea Biomedicine Industry Association
한국바이오의약품협회

COVANCE®
SOLUTIONS MADE REAL®